MarketLens

GSK's Growth Paradox: Why Strong Earnings Aren't Lifting the Stock

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Heartflow's AI-Driven Upside: Why CEO Sales Aren't the Full Story

2 months ago

Why Did GSK Pay $10.6 Billion for Nuvalent

3 months ago

Is the Semiconductor Boom Lifting All Boats, or Just the AI Yachts

5 months ago

What is the Significance of Lynavoy's FDA Approval for GSK

3 months ago

GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?

GSK shares fell 14% in six months, pressured by investor concerns, while Specialty Medicines growth and a robust pipeline could support long-term recovery if execution holds.

GSK

Stock News•1 months ago

GSK hits three-month high as vaccines help earnings top forecasts

GSK shares hit a three-month high after beating Q2 expectations across key measures, driven by strong vaccine sales.

GSK.L

Stock News•1 months ago

GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment

GSK shares fell after the drugmaker dropped its experimental chronic cough treatment due to limited efficacy in late-stage studies.

GSK

Breaking News

Event-Driven Investing

Top Headlines

View More →

Stock News•1 hour ago

$10,000 in Tesla When It Joined the S&P 500 Would Be About $15,700 Today. An Index Fund Would Have Done Better.

Stock News•4 hours ago

J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion

Stock News•5 hours ago

Google's Historic 396 MW Clean Energy Deal Just Changed the Game for 1 AI Power Play

Stock News•6 hours ago

Better AI Chip Stock: Broadcom vs. Nvidia

Stock News•6 hours ago

GSK's Growth Paradox: Why Strong Earnings Aren't Lifting the Stock

Exclusive Content for Pro Members

Related Articles

Heartflow's AI-Driven Upside: Why CEO Sales Aren't the Full Story

Why Did GSK Pay $10.6 Billion for Nuvalent

Is the Semiconductor Boom Lifting All Boats, or Just the AI Yachts

What is the Significance of Lynavoy's FDA Approval for GSK

Category

You may also like

GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?

GSK hits three-month high as vaccines help earnings top forecasts

GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment

Breaking News

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Top Headlines

$10,000 in Tesla When It Joined the S&P 500 Would Be About $15,700 Today. An Index Fund Would Have Done Better.

J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion

Google's Historic 396 MW Clean Energy Deal Just Changed the Game for 1 AI Power Play

Better AI Chip Stock: Broadcom vs. Nvidia

Dell Technologies Sees AI Boom Building as $95B Server Backlog Signals Demand